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Abstract
Objective: Describe the Vaccine Safety Datalink’s (VSD) Guillain Barré Syndrome (GBS) 
surveillance following quadrivalent HPV vaccine (4vHPV) from 2006 through 2015.
Methods: Among 4vHPV vaccinated persons aged 9–26, ICD-9 coded GBS was identified in 
VSD’s electronic data. Medical records were reviewed and adjudicated to confirm GBS. We 
calculated incidence rates of confirmed GBS within 1–42 days following 4vHPV with a one-sided 
95% confidence interval.
Results: Following 2,773,185 4vHPV doses, we confirmed 1 case of GBS in a male and no cases 
among females. The incidence rate of medical record confirmed GBS within 42 days following 
4vHPV vaccine was 0.36 cases per million 4vHPV doses administered (1-sided 95% CI 1.71), 
which was less than the background rate.
Conclusion: We found no evidence of an increased risk of GBS following 4vHPV. With an 
upper 95% confidence limit, we estimate that, if an increased risk exists, we would expect at most 
1.08 additional cases of GBS per million people vaccinated with 4vHPV.
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1. Background
Guillain Barré Syndrome (GBS) is a rare, serious autoimmune disorder of the peripheral 
nerves characterized by muscle weakness and loss of reflexes [1]. Estimated GBS incidence 
ranges from0.8 to 1.9 cases per 100,000 person-years; the rate is higher in males and 
increases with age [2]. The exact cause of GBS is unknown; however, molecular mimicry is 
hypothesized to be the mechanism for antigenic stimulation with resulting autoimmune 
demyelination and damage to peripheral nerves [3,4]. Approximately two-thirds of patients 
with GBS describe symptoms of gastrointestinal (e.g., Campylobacter jejuni) or respiratory 
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infection within few weeks prior to onset [5]. Rarely, GBS occurs following vaccination. 
During the 1976 swine influenza vaccination program, GBS was found to be increased in the 
six weeks following vaccination [6]. Since then, findings for post-vaccination GBS have 
been inconsistent for influenza vaccines and reassuring for other vaccines [7–10]. Because 
of this history, GBS is an outcome of interest for vaccine safety surveillance, particularly 
when new vaccines are licensed and recommended.
Since 2006, human papillomavirus vaccine (HPV) vaccine has been routinely recommended 
in the United States for girls aged 11 or 12 and through age 26 years for those not previously 
vaccinated. In 2011, the recommendation was expanded to include routine vaccination of 
males. Through 2015, almost all HPV vaccine used in the United States was 4vHPV. To 
date, no safety concerns for GBS following HPV vaccines have been observed in the US 
spontaneous monitoring system, the Vaccine Adverse Event Reporting System [11,12]. 
Large population-based studies in the US, France, England, and Scandinavia have found no 
increased risk of GBS following HPV vaccination [13–16]. In 2017, however, the French 
National Agency for Medicines and Health Products Safety published findings from a 
retrospective cohort study using healthcare administrative databases and no medical record 
review evaluating 14 autoimmune conditions. This study detected robust statistical 
associations with GBS following HPV vaccination in girls in their general analyses and 
several sensitivity analyses [17].
The Vaccine Safety Datalink (VSD), a collaboration between CDC and several integrated 
health care plans, has been a cornerstone of U.S. population-based vaccine safety 
surveillance for over 25 years [18]. VSD links health outcome and vaccination data to 
monitor vaccine safety in near-real-time using a rapid cycle analysis (RCA) method, which 
has been described elsewhere [19]. VSD conducted 4vHPV RCA from August 2006 through 
October 2009 and observed 0 GBS cases following 600,558 doses among females 9–26 
years of age. Because GBS is rare, the power to detect a risk was limited. Therefore, VSD 
continued long term surveillance. The objective of this report is to describe the findings of 
VSD’s GBS surveillance following 4vHPV from 2006 through 2015.
2. Methods
Six VSD sites contributed data to this prospective 4vHPV surveillance of GBS. The 
population under surveillance included males and females aged 9–26 years who received 
4vHPV at participating sites between August 1, 2006-December 31, 2015 (after which 
9vHPV replaced 4vHPV). One VSD site began contributing data starting April 2008. 
Among 4vHPV vaccine recipients, we identified all potential electronic ICD-9 coded cases 
of GBS using the following definition: diagnostic ICD-9 code 357.0 within 1–42 days post-
vaccination (whereas day 0 is day of vaccination), in either the inpatient, outpatient, or 
emergency department settings. An incident case of GBS following 4vHPV was defined as 
the first diagnosis in the preceding 42 days.
We conducted medical record reviews for potential cases of GBS. VSD medical 
epidemiologists conducted adjudication using Brighton Collaboration case definition criteria 
to classify cases [1]. Diagnostic certainty is higher for cases assigned a Brighton 
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Collaboration case definition of level 1. The Institutional Review Boards at all participating 
sites approved this study.
We calculated medical record confirmed incidence rates of GBS within 1–42 days following 
4vHPV. We then calculated a one-sided 95% confidence interval using the exact Poisson 
method around these rates. Using the exact Poisson method, we obtained the upper bound of 
the one-sided 95% confidence interval for the attributable risk of GBS per million 
vaccinations. Using a published background rate of 0.55 chart-confirmed GBS cases per 
100,000 person years among a population aged 11–18 years, we calculated the expected 
number of cases per 1 million vaccine doses [20]. In order to produce the upper bound of the 
one-sided 95% confidence interval for the attributable risk of GBS per 1 million 4vHPV 
vaccinations, we subtracted the expected number of cases from the upper bound of the 
confidence interval for the incidence rate of GBS. We also performed this calculation on all 
cases identified from electronic data.
3. Results
From August 2006 through December 31, 2015, 2,773,185 doses of 4vHPV were 
administered in the study population: 1,900,370 doses among females and 872,815 doses 
among males. Seven cases of GBS were identified using the electronic case definition prior 
to medical record review: 4 cases in females and 3 in males. The overall electronic potential 
GBS case incidence rate was 2.52 cases per million 4vHPV doses administered (95% CI 
1.01, 5.20); 2.10 per million doses for females (95% CI: 0.057, 5.39) and 3.44 per million 
doses for males (95% CI: 0.71, 10.04). After performing medical record review, we observed 
one incident case of Acute Inflammatory Demyelinating Polyneuropathy, the most common 
form of GBS. Among the six cases that were not confirmed, five had a prior history of GBS 
and one was determined not to be GBS (Table 1).
On medical record review, we identified 0 confirmed cases among females and one 
confirmed case in a male. This single confirmed case met Brighton Collaboration case 
definition Level 4-reported GBS with insufficient evidence to meet the case definition levels 
1–3. The overall incidence rate of medical record confirmed GBS within 42 days for both 
sexes combined following 4vHPV vaccine was 0.36 cases per million 4vHPV doses 
administered, which was not higher than the expected background rate. The 1-sided upper 
95% confidence limit was 1.71 cases per million doses (Table 2). Based on the upper 95% 
confidence limit, a potential increased risk of GBS associated with 4vHPV would be at 
most1.08 cases per million doses.
4. Discussion
To our knowledge, this is the first study to evaluate GBS following 4vHPV in males and 
females. We identified only one confirmed incident GBS case in a male during the 9 year 
surveillance period and no cases among females. Among an estimated 1,708,075 vaccinated 
patients, we found no increased risk of GBS in the 42 days following receipt of 4vHPV.
The capability to exclude a small excess risk of 4vHPV-associated GBS reflects the strength 
of the VSD, which routinely collects high quality vaccination and health outcome data in a 
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large population. The ability to access the medical records in VSD allows for well-validated 
incidence rates to be generated. Had we relied on electronic data alone, our rates of GBS 
following 4vHPV would have been falsely elevated and potentially misleading. Our medical 
record reviews confirmed that only 1 of the 7 GBS cases initially identified (among 
2,773,185 4vHPV doses administered) was an incident case. Of the remaining cases, 5 had a 
prior history of GBS and 1 was determined not to be GBS.
With the exception of the French database study [17], no study observed an increased risk of 
GBS [13–16]. Few of the large population-based studies on HPV vaccines and GBS have 
employed medical record validation. Based on our GBS case validation findings, it is 
reasonable to assume that if other large population-based studies had conducted medical 
record review, the results may have shown lower rates of GBS following exposure. The 
French study, which analyzed electronic administrative healthcare data on 2.25 million 
females aged 13–16 years between January 2008 and December 2012 without medical 
record review, found 19 GBS cases among those vaccinated and 21 cases in unvaccinated 
females during the overall follow-up period. This study observed a significant association in 
the first 0–2 months. The strength of the significant association decreased with the longer 
exposure windows between 2 and 12 months and reached non-significancy > 12 months 
following vaccination. Some of the chosen risk windows for this study were longer than the 
traditionally accepted risk window for GBS following vaccination of 1–42 days [6]. This 
may account for some of the findings; longer risk windows may increase the potential for 
bias and confounding.
Our study has some limitations. We used a published background rate of GBS among 11–18 
year olds from five US health plans [20]. While this rate did not include adolescents aged 9–
10 years and 19–26 years, we still considered this rate to be comparable since it involved a 
similar US adolescent population. Another limitation was potential loss to follow-up among 
those males and females aged 18–26 years as it is possible that some older members may 
utilize college based insurance. However given the cost of hospitalization, we would expect 
that this diagnosis would be reliably captured in our VSD data under the family’s primary 
insurance.
Among an estimated 1,708,075 vaccinees, we confirmed only one incident case of GBS, 
which is in line with the background rate. Even if we make the conservative assumption that 
an increased risk may be as high as the upper 95% confidence limit of our estimate, we 
would expect at most 1.08 additional cases of GBS per million people vaccinated with 
4vHPV.
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